EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Novel Transthoracic Pulmonary Valve Implantation Using Self‐Expanding Salus Valve: A Prospective Study of Safety and Mid‐Term Outcomes

Ziqin Zhou iD, Miao Tian, Jiazichao Tu, Yong Zhang, Jian Zhuang, Shusheng Wen, Jimei Chen

Catheterization and Cardiovascular Interventions · 2025

DOI: 10.1002/ccd.31471 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Catheterization and Cardiovascular Interventions, 2025. Verfasst von Ziqin Zhou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guan…. Hauptthemen laut MEDLINE: Pulmonary Valve, Heart Valve Prosthesis Implantation, Pulmonary Valve Insufficiency, Heart Valve Prosthesis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: This work is supported by the project of Guangdong Provincial Research Institution Innovation Capability Construction Stability Support Program (KD022023019),….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Transcatheter pulmonary valve replacement (TPVR) has emerged as a valuable treatment for severe pulmonary regurgitation (PR). The Salus valve (Balance Medical Technology Co. Ltd., Beijing, China) represents a novel self‐expanding valve stent designed for deployment through a transthoracic approach with a small subxiphoid incision.

Aims

The objective of this study was to evaluate the medium‐term safety and efficacy of Salus valve stents in this patient population.

Methods

This prospective cohort study enrolled patients who underwent transthoracic pulmonary valve stenting at Guangdong Provincial People's Hospital from September 2021 to September 2024. Inclusion criteria included moderate‐to‐severe PR following RVOT reconstruction, age ≥ 14 years, and specific clinical/imaging parameters. Primary endpoints were pulmonary regurgitation fraction < 20%, freedom from reintervention at 12 months, and major adverse events (MAE). MAE were defined as death, reintervention, recurrent severe PR, worsening heart failure, cardiac arrest, new severe ventricular arrhythmias, and third‐degree AV block.

Results

Among 38 patients (mean age 24.08 ± 8.12 years), all procedures were successfully completed, although intraoperative valve displacement occurred in three cases. During a median follow‐up period of 24 months, significant improvements were observed in right ventricular volumes: Right Ventricular End‐Diastolic Volume Index (RVEDVI) decreased from 141.45 to 109.98 mL/m 2 and Right Ventricular End‐Systolic Volume Index (RVESVI) decreased from 74.27 to 56.62 mL/m 2 (both p < 0.01). No mortality or need for reintervention was observed during the follow‐up period. The estimated freedom from major adverse events at 36 months was 87.2%.

Conclusion

The Salus valve demonstrated safety and efficacy for severe PR treatment through its transthoracic approach, which offers unique advantages in terms of direct access and immediate complication management. Longer follow‐up is needed to assess long‐term durability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary ValveHeart Valve Prosthesis ImplantationPulmonary Valve InsufficiencyHeart Valve ProsthesisCardiac CatheterizationStentsHumansProspective StudiesFemaleMaleTime FactorsProsthesis DesignAdultTreatment OutcomeYoung AdultRecovery of FunctionAdolescentSeverity of Illness IndexRisk FactorsHemodynamics

Stichwörter der Autor:innen

congenital heart diseasepulmonary valve regurgitationright ventricular functionright ventricular outflow tractself‐expanding pulmonary valve stent

Autor:innen und Institutionen

  • Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.

ORCID-Profile: Ziqin Zhou

Förderung

  • This work is supported by the project of Guangdong Provincial Research Institution Innovation Capability Construction Stability Support Program (KD022023019),…

Zitieren

APA

Zhou, Z., Tian, M., Tu, J., Zhang, Y., Zhuang, J., Wen, S., & Chen, J. (2025). Novel Transthoracic Pulmonary Valve Implantation Using Self‐Expanding Salus Valve: A Prospective Study of Safety and Mid‐Term Outcomes. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.31471

Vancouver

Zhou Z, Tian M, Tu J, Zhang Y, Zhuang J, Wen S, et al. Novel Transthoracic Pulmonary Valve Implantation Using Self‐Expanding Salus Valve: A Prospective Study of Safety and Mid‐Term Outcomes. Catheterization and Cardiovascular Interventions. 2025. doi:10.1002/ccd.31471

BibTeX
@article{Zhou2025,
  author = {Zhou, Ziqin and Tian, Miao and Tu, Jiazichao and Zhang, Yong and Zhuang, Jian and Wen, Shusheng and Chen, Jimei},
  title = {Novel Transthoracic Pulmonary Valve Implantation Using Self‐Expanding Salus Valve: A Prospective Study of Safety and Mid‐Term Outcomes},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2025},
  doi = {10.1002/ccd.31471}
}
Kostenlos starten →